Sonya Ludmilla Eremenco’s early training focused on linguistics and cross-cultural communication, which are fundamental to the translation and linguistic validation of patient-reported outcomes (PRO) measures and other clinical outcome assessments (COAs). With over 25 years in the COA development and evaluation field, her research interests include multicultural COA development (particularly PRO measures) as well as electronic implementation and equivalence, in addition to linguistic validation. Since joining the Critical Path Institute in August 2016, she has played an instrumental role in the FDA qualification of five COAs, including: symptoms of major depressive disorder scale (SMDDS) and the diary for irritable bowel syndrome symptoms – constipation (DIBSS-C). She is also the scientific lead for three PRO Measurement Information System® (PROMIS®) measures in the FDA COA Qualification Program:  PROMIS Fatigue Short Form 10a for rheumatoid arthritis, PROMIS Short Form v1.0—Fatigue-Multiple Sclerosis 8a, and PROMISnq Short Form v2.0 – Physical Function – Multiple Sclerosis 15a.